What Tramontane Therapeutics does

Tramontane Therapeutics is a gene therapy company developing AAV vector-based treatments for prevalent metabolic and neurodegenerative diseases, including Nonalcoholic Steatohepatitis (NASH), Type 2 diabetes, obesity, Alzheimer's disease, and Parkinson's disease. The company was founded in 2019 as a spinout from the Universitat Autònoma de Barcelona (UAB), with scientific leadership from co-founder Fátima Bosch, Ph.D., Professor of Biochemistry and Molecular Biology at UAB. Its core technology centers on adeno-associated virus (AAV) vectors engineered to enable continuous, steady-state expression of therapeutic proteins — most notably native Fibroblast Growth Factor 21 (FGF21) — through a one-time intramuscular administration, eliminating the peak-to-trough pharmacokinetic variability and compliance burden associated with repeatedly-injected recombinant analog products.

The company's lead program is an AAV vector designed to express native FGF21 protein for the treatment of NASH, an indication affecting approximately 17 million people in the United States for which no FDA-approved therapies exist to halt or reverse disease progression. Tramontane's portfolio also includes gene therapy candidates targeting Type 2 diabetes, obesity, Alzheimer's disease, and Parkinson's disease, with efficacy and durability established across multiple validated animal models. On September 6, 2023, Tramontane was acquired by Kriya Therapeutics and now operates as a wholly owned subsidiary within Kriya's Metabolic Disease portfolio.

As a preclinical-stage biotechnology company, Tramontane has had no commercial revenue, no marketed products, and no direct customer relationships. Its business model is research-and-development oriented: advancing gene therapy candidates through preclinical validation toward clinical entry — with Kriya anticipating advancement of the NASH candidate into the clinic by the first half of 2025. Following the acquisition, commercial infrastructure, manufacturing, and pipeline development are subsumed within Kriya Therapeutics, which has raised over $600 million in committed capital and operates facilities in Palo Alto, California and Research Triangle Park, North Carolina.

Name

Tramontane Therapeutics

Legal name

Tramontane Therapeutics, Inc.

Website

https://tramontanetx.com

Company type

Private

Founded year

2019

Operating status

Acquired

Short description

Tramontane Therapeutics is a preclinical gene therapy company developing AAV vector-based treatments for metabolic and neurodegenerative diseases, including NASH, Type 2 diabetes, obesity, Alzheimer's, and Parkinson's. Founded in 2019 as a UAB spinout and acquired by Kriya Therapeutics in September 2023.

Ownership category

akta.pro rank

Product category

Gene Therapy

NAICS

Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

AAV Vector Gene Therapy Developers (HLAAACAA)

akta.pro secondary industries

Neurology/CNS Gene Therapies (HLAAACAH), Cardiometabolic & Other Systemic Gene Therapies (HLAAACAI)

Keywords

• Gene therapy
• AAV vector therapy
• Metabolic disease treatment
• Neurodegenerative disease therapy
• FGF21 protein therapy

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations

Core offering

Tramontane Therapeutics develops adeno-associated virus (AAV) vector-based gene therapies targeting metabolic and neurodegenerative diseases. Its lead program is an AAV vector designed to express a steady level of native FGF21 protein via one-time intramuscular administration for the treatment of Nonalcoholic Steatohepatitis (NASH). Additional pipeline candidates use AAV vectors to express therapeutic proteins for Type 2 diabetes, obesity, Alzheimer's disease, and Parkinson's disease.

Product overview

Tramontane Therapeutics is a gene therapy company focused on developing treatments for prevalent neurodegenerative and metabolic diseases using adeno-associated viral (AAV) vectors. The company, spun out from Universitat Autònoma de Barcelona (UAB), was acquired by Kriya Therapeutics in September 2023. Its portfolio includes FGF21 gene therapy programs for NASH (lead program), Type 2 diabetes, obesity, Alzheimer's disease, and Parkinson's disease. The core technology platform uses AAV vectors to express therapeutic proteins with continuous expression for chronic diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• FGF21 Gene Therapy Program Lead program: an adeno-associated virus (AAV) vector designed to express a steady level of native FGF21 protein for treating Nonalcoholic Steatohepatitis (NASH). One-time intramuscular gene therapy enabling continuous expression of native FGF21 with potential for better efficacy, safety, tolerability and pharmacokinetic profile than other products in development.
• Type 2 Diabetes Gene Therapy Gene therapy candidate for insulin-dependent (Type 2) diabetes, utilizing AAV vectors to express therapeutic proteins for metabolic disease management.
• Obesity Gene Therapy Gene therapy candidate utilizing AAV vectors to express therapeutic proteins for obesity treatment, with strong efficacy and durability established across multiple validated animal models of obesity.
• Alzheimer's Disease Gene Therapy Gene therapy candidate for Alzheimer's disease using adeno-associated viral vectors to express therapeutic proteins targeting central disorders associated with impaired cognition.
• Parkinson's Disease Gene Therapy Gene therapy candidate for Parkinson's disease using AAV vectors to express therapeutic proteins targeting central disorders associated with impaired cognition and behavior.

Quantifiable outcome

• FGF21 is a clinically-validated biological target in NASH; approximately 20 percent of people with NASH will progress to advanced liver disease over several years or decades

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Recent moves3 records

Expansion highlights4 records

Broad incumbents

• Pfizer: Large pharmaceutical company with a broad AAV gene therapy portfolio across hemophilia, rare diseases, and metabolic indications. Comparable as a broad incumbent with AAV capabilities and resources that dwarf Tramontane/Kriya's, though not focused on Tramontane's specific FGF21 approach.
• Novartis: Global pharmaceutical company that commercializes Zolgensma, the first FDA-approved AAV gene therapy (for SMA). A broad incumbent with proven AAV manufacturing, regulatory, and commercialization capabilities relevant to Tramontane's chronic disease gene therapy approach, though focused on different therapeutic areas.
• BioMarin Pharmaceutical: Commercial-stage biopharmaceutical company with an AAV gene therapy franchise (Roctavian for hemophilia A) and metabolic disease portfolio. A broad incumbent with established AAV manufacturing, regulatory experience, and metabolic disease commercial infrastructure relevant to Tramontane's NASH ambitions.

Direct peers

• Voyager Therapeutics: Clinical-stage gene therapy company developing AAV-based treatments primarily for CNS diseases including Parkinson's disease, Huntington's disease, and ALS. Directly comparable on AAV platform technology and on the neurological indications (Parkinson's, Alzheimer's) overlapping with Tramontane's pipeline.
• uniQure: Clinical-stage gene therapy company developing AAV-based therapies for metabolic and CNS diseases, including programs for Huntington's disease and hemophilia B. Directly comparable to Tramontane on AAV vector technology and therapeutic area breadth across neurological and metabolic indications.
• Akero Therapeutics: Clinical-stage biopharmaceutical company developing efruxifermin (EFX), an FGF21 analog, for NASH. Targets the same validated biology as Tramontane's FGF21 gene therapy, though via a recombinant protein rather than one-time AAV delivery — making it the closest mechanistic competitor in the lead indication.
• Madrigal Pharmaceuticals: Developer of resmetirom (Rezdiffra), the first FDA-approved therapy for NASH (approved March 2024). Represents the now-established standard of care in Tramontane's lead indication and a key benchmark against which any new NASH therapy — including AAV-FGF21 — must demonstrate clinical and economic value.
• 89bio: Clinical-stage company developing pegozafermin, a long-acting FGF21 analog for NASH and severe hypertriglyceridemia. Directly comparable to Tramontane's lead program in target (FGF21) and indication (NASH), representing a near-term competitive threat with a more clinically advanced profile.

Emerging players

• Solid Biosciences: Clinical-stage gene therapy company developing AAV-based treatments for Duchenne muscular dystrophy and other rare diseases. An emerging player in the AAV gene therapy space with comparable platform technology and preclinical/early-clinical stage profile, though focused on different indications.
• Passage Bio: Clinical-stage gene therapy company developing AAV-delivered treatments for CNS diseases including frontotemporal dementia, Huntington's disease, and Krabbe disease. An emerging player whose AAV platform and CNS focus overlap with Tramontane's neurological pipeline (Alzheimer's, Parkinson's).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tramontane Therapeutics